AptaBio "Harvard University Endosome Target Blocks COVID-19 Spread in US... APX-115 Combination Therapy Excellent"

‘APX-115’ Confident in COVID-19 Treatment Effect
Developing Endosome-Targeted Therapy…Excellent Combined Treatment Effect with Two Additional Mechanisms

[Asia Economy Reporter Hyungsoo Park] Aptabio, a developer of anticancer and diabetic complication treatments, announced on the 11th that the efficacy of its novel coronavirus disease (COVID-19) treatment candidate is gaining attention.

According to a recent study from Harvard University, the U.S. pharmaceutical company Cinta Pharmaceuticals' 'Apilimod' has been confirmed to be effective in preventing the spread of the COVID-19 virus within the body. Apilimod inhibits the formation of 'endosomes,' which are involved in intracellular material transport, thereby blocking viral movement and replication inside cells.

An Aptabio official stated, "'APX-115' also acts via a mechanism targeting endosomes, similar to Apilimod," adding, "The proven efficacy of therapeutics with similar mechanisms is significant for Aptabio in developing its treatment."

They continued, "APX-115 inhibits the endosomal enzyme 'NOX2' and suppresses reactive oxygen species (ROS), fundamentally blocking viral movement through endosomes."

As additional research results suggest that inhibiting endosome activity is a key to controlling the spread of the COVID-19 virus within the body, it is expected that research on APX-115 will accelerate.

A company representative emphasized, "The candidate APX-115 is a complex NOX inhibitor therapeutic with two additional mechanisms of action beyond the endosome-targeting mechanism," and added, "We expect its therapeutic effect to be superior to other candidates."

Aptabio confirmed through cell experiments that APX-115 is effective in inducing the death of infected cells, similar to remdesivir, a leading COVID-19 treatment candidate. It also demonstrated functions for treating pneumonia and pulmonary fibrosis, introducing that three mechanisms collectively act to treat COVID-19.

APX-115, developed by Aptabio, has already completed Phase 1 clinical trials in Europe, proving its safety and absence of side effect issues.

This content was produced with the assistance of AI translation services.